ATE320444T1 - Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren - Google Patents

Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren

Info

Publication number
ATE320444T1
ATE320444T1 AT92307785T AT92307785T ATE320444T1 AT E320444 T1 ATE320444 T1 AT E320444T1 AT 92307785 T AT92307785 T AT 92307785T AT 92307785 T AT92307785 T AT 92307785T AT E320444 T1 ATE320444 T1 AT E320444T1
Authority
AT
Austria
Prior art keywords
peptides
hbv
virus
cytotoxic
hepatitis
Prior art date
Application number
AT92307785T
Other languages
English (en)
Inventor
Francis V Chisari
Carlo Ferrari
Amalia Penna
Gabriele Missale
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE320444T1 publication Critical patent/ATE320444T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT92307785T 1991-08-26 1992-08-26 Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren ATE320444T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74954091A 1991-08-26 1991-08-26

Publications (1)

Publication Number Publication Date
ATE320444T1 true ATE320444T1 (de) 2006-04-15

Family

ID=25014174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92307785T ATE320444T1 (de) 1991-08-26 1992-08-26 Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren

Country Status (19)

Country Link
EP (1) EP0534618B1 (de)
JP (3) JP3566284B2 (de)
AT (1) ATE320444T1 (de)
AU (1) AU679901B2 (de)
BG (1) BG98522A (de)
CA (1) CA2115927C (de)
CZ (1) CZ42894A3 (de)
DE (1) DE69233607T2 (de)
DK (1) DK0534618T3 (de)
ES (1) ES2262132T3 (de)
FI (1) FI940919L (de)
HU (1) HUT67529A (de)
IL (1) IL102963A0 (de)
NO (1) NO940661L (de)
NZ (2) NZ244102A (de)
OA (1) OA09889A (de)
PT (1) PT534618E (de)
WO (1) WO1993003753A1 (de)
ZA (1) ZA926440B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
CA2168583C (en) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
DE69820486D1 (de) * 1998-01-19 2004-01-22 Mogam Biotechnology Res Inst Y Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
GB0328753D0 (en) * 2003-12-11 2004-01-14 Royal Veterinary College The Hepatitis B vaccines
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CA2955604A1 (en) * 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939900A (de) * 1972-08-25 1974-04-13
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Also Published As

Publication number Publication date
DE69233607D1 (de) 2006-05-11
IL102963A0 (en) 1993-01-31
BG98522A (bg) 1995-05-31
FI940919A7 (fi) 1994-04-25
NO940661D0 (no) 1994-02-25
PT534618E (pt) 2006-08-31
OA09889A (en) 1994-09-15
EP0534618A3 (en) 1993-06-30
CA2115927A1 (en) 1993-03-04
AU679901B2 (en) 1997-07-17
HUT67529A (en) 1995-04-28
DK0534618T3 (da) 2006-07-24
JP3694299B2 (ja) 2005-09-14
JP2003267997A (ja) 2003-09-25
CA2115927C (en) 2009-04-21
JP3694300B2 (ja) 2005-09-14
JP3566284B2 (ja) 2004-09-15
EP0534618B1 (de) 2006-03-15
JPH06510050A (ja) 1994-11-10
NZ270625A (en) 1996-12-20
JP2003300999A (ja) 2003-10-21
AU2540892A (en) 1993-03-16
FI940919A0 (fi) 1994-02-25
FI940919L (fi) 1994-04-25
ZA926440B (en) 1993-06-07
ES2262132T3 (es) 2006-11-16
DE69233607T2 (de) 2006-11-30
NO940661L (no) 1994-04-19
EP0534618A2 (de) 1993-03-31
WO1993003753A1 (en) 1993-03-04
NZ244102A (en) 1996-12-20
CZ42894A3 (en) 1995-02-15
HU9400582D0 (en) 1994-07-28

Similar Documents

Publication Publication Date Title
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
DE69431665D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
EP1018344A3 (de) HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus
DE69625802D1 (de) Impfstoffe gegen die pest
GB2255093A (en) Hiv-1 core protein fragments
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE69007571D1 (de) Peptidfragmente von HIV.
ATE204760T1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации
RU94038427A (ru) Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0534618

Country of ref document: EP